Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe Sells 564 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 564 shares of the business's stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $48.25, for a total value of $27,213.00. Following the completion of the sale, the senior vice president owned 2,903 shares of the company's stock, valued at approximately $140,069.75. This trade represents a 16.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Thursday, July 3rd, Jolanda Howe sold 477 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $49.08, for a total value of $23,411.16.

Mirum Pharmaceuticals Stock Up 1.7%

Shares of NASDAQ MIRM traded up $0.84 during midday trading on Friday, hitting $49.93. The stock had a trading volume of 216,684 shares, compared to its average volume of 465,058. The business's 50 day moving average is $46.27 and its 200-day moving average is $45.44. Mirum Pharmaceuticals, Inc. has a 52 week low of $33.64 and a 52 week high of $54.23. The company has a quick ratio of 3.04, a current ratio of 3.22 and a debt-to-equity ratio of 1.32. The company has a market cap of $2.47 billion, a P/E ratio of -31.01 and a beta of 0.97.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 33.63% and a negative net margin of 20.39%. The business had revenue of $111.59 million during the quarter, compared to analyst estimates of $98.47 million. During the same quarter last year, the company earned ($0.54) EPS. The company's quarterly revenue was up 61.2% compared to the same quarter last year. As a group, analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Wall Street Analyst Weigh In

MIRM has been the subject of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $73.00 target price on shares of Mirum Pharmaceuticals in a report on Monday, May 19th. Raymond James Financial reaffirmed a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 13th. JMP Securities lifted their price objective on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a report on Friday, May 9th. Finally, Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Mirum Pharmaceuticals currently has an average rating of "Buy" and an average price target of $65.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its stake in Mirum Pharmaceuticals by 4,555.0% during the 1st quarter. GAMMA Investing LLC now owns 5,586 shares of the company's stock valued at $252,000 after buying an additional 5,466 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Mirum Pharmaceuticals by 174.9% in the first quarter. SG Americas Securities LLC now owns 19,182 shares of the company's stock worth $864,000 after acquiring an additional 12,204 shares during the period. MPM Bioimpact LLC increased its position in Mirum Pharmaceuticals by 19.7% during the fourth quarter. MPM Bioimpact LLC now owns 589,579 shares of the company's stock valued at $24,379,000 after acquiring an additional 96,856 shares during the last quarter. AlphaQuest LLC increased its position in Mirum Pharmaceuticals by 969.6% during the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after acquiring an additional 1,658 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $277,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.